Spectramed to Offer the Aspire 2, A NMES & sEMG Biofeedback System Used for the Treatment of Dysphagia and Other Swallowing Disorders

Share Article

Spectramed, the 23-year-old medical manufacturing and project development company founded by a team of expert practicing clinicians who specialize in Dysphagia Therapy, will release in 2015 the most advanced Neuro Muscular Electrical System (NMES) ever designed to treat suffers of feeding and swallowing disorders. Approximately 15 million Americans are evaluated each year with swallowing difficulties, which can result from stroke, brain injury, spinal cord injury, Parkinson’s disease, multiple sclerosis, ALS, Muscular Dystrophy, Cerebral Palsy, Alzheimer’s and Head & Neck Cancer.

Spectramed, the 23-year-old medical manufacturing and project development company founded by a team of expert practicing clinicians who specialize in Dysphagia Therapy, will release in 2015 the most advanced Neuro Muscular Electrical System (NMES) ever designed to treat suffers of feeding and swallowing disorders. Approximately 15 million Americans are evaluated each year with swallowing difficulties, which can result from stroke, brain injury, spinal cord injury, Parkinson’s disease, multiple sclerosis, ALS, Muscular Dystrophy, Cerebral Palsy, Alzheimer’s and Head & Neck Cancer.

The Guardian Way®, a clinical philosophy driven by compassion for patient care and product innovation. The methods and tools are designed by clinicians for clinicians. The Aspire 2 sEMG / Biofeedback tools utilize software to record data from stimulation applied to the patient. This proprietary stimulation protocol initiates swallowing and the software allows the clinician to record information on the progress of the patient. The Guardian Way® is a fully interactive rehabilitation suite combined with tools to address the needs of specific populations.

“No device out there allows the speech language pathologist to get initial swallowing assessment evaluations,” according to Rick Fisher, President and Chief Executive Officer of Spectramed. “As a result, this device will provide initial patient assessment but also ongoing objective data to prove clinical gains. The Guardian Way® is truly a game changing clinical philosophy combined with effective tools and treatment methods with unparalleled outcomes ”

The Aspire2 sEMG Biofeedback system and The Guardian Way® are FDA approved. Additionally, the system is supported by Medicare, as a result of the Medicare Modernization Act, enacted by the government to allow coverage of equipment that can measure objective data.

Spectramed acquired in 2005 by Rick and Nathan Fisher with over 40 years of combined medical manufacturing experience. They started development of The Guardian Way© system in 2010, and were joined by Speech Language Pathologist & Multiple Sclerosis Certified Specialist Marissa Barerra, MS, MPHIL, MSCS, TSHH, CCC-SLP; Language Pathologist Teresa Biber, MS, CCC-SLP; Physical Therapist Dr. Emil Euaparadorn, PT, DSC, OCS, COMT, CMPT, MSCS, CSCS, FAAOMPT; Physical Therapist Dr. Robert J. Schreyer, PT, DPT, NCS, MSCS, CSCS; and pediatric feeding and swallowing disorders expert Nancy C. Calamusa, MA, CCC-SLP.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Richard Fisher
Visit website